Menu

Recent Interviews

Alison Coutts, Executive Chairman, Memphasys Ltd.

Alison Coutts
Executive Chairman | Memphasys Ltd.
30 Richmond Road, 2140 Homebush West (AUS)

alison.coutts@memphasys.com

+61 2 8415 7300

Memphasys Executive Chairman Alison Coutts on in vitro fertilisation (IVF)


Thomas Soltau, CEO, wallstreet:online capital AG

Thomas Soltau
CEO | wallstreet:online capital AG
Michaelkirchstraße 17/18, 10179 Berlin (D)

service@smartbroker.de

+49 30 27 57 76 464

Smartbroker - wallstreet:online capital AG CEO Thomas Soltau in an interview on the market launch


Jonathan Summers, CEO, EXMceuticals Inc.

Jonathan Summers
CEO | EXMceuticals Inc.
1111 Alberni Street, Suite 1603, V6E 4V2 Vancouver (CAN)

jonathan@exmceuticals.com

EXMceuticals CEO Jonathan Summers on the medical cannabis market


15. January 2020 | 07:42 CET

Fresenius Peer: Will the analysts' favorite M1 Kliniken 2020 take off?

  • Medical

Besides Fresenius, M1 Klinken AG is one of the few listed clinic operators in Germany. Unlike the clinic group, M1 has specialised in a lucrative niche: the beauty market. More and more people are helping with beauty and are generating billions in sales in the industry. In just a few years, M1 has become the market leader for beauty medicine in Germany. A growth rate of 30% is also targeted for the future. Foreign business is increasingly becoming the growth driver. After a continuous price increase between 2016 and 2018, the share has consolidated in 2019. But operationally things are still running smoothly. Analysts see more than 50% upside potential.

time to read: 1 minutes by Mario Hose


 

All analysts convinced of growth course

All analysts - including Commerzbank and Bankhaus Metzler - are convinced that M1 Kliniken will continue to grow at double-digit rates in the coming years and recommend the share as a buy. Five analysts expect M1 Kliniken to break through the EUR 100 million revenue barrier this year (2018: EUR 65 million). The average expectation for net income in 2020 is EUR 9.8 million (2018: EUR 6.6 million).

Sales and profit growth foreseeable

M1 has already laid the foundation for further revenue and profit growth in the current year. In 2019, 12 new specialist centres were opened, significantly more than in previous years (average 6 p.a.). This means that the Group now operates 36 outpatient centres for aesthetic medicine. With Dortmund, Bielefeld, Rostock, Stuttgart II and Frankfurt (M1 Dental), M1 has increased the number of locations in Germany by 5 to 28.

In addition, larger premises were moved into Hamburg and Hanover. At the same time, M1 is specifically increasing the range of treatments offered in the existing specialist centres. For example, aesthetic laser treatments, such as hair removal, are now offered at 20 beauty locations under the "M1 Laser" brand.

Internationalization as growth driver

International expansion was added as an additional growth driver last year. After the first international "M1 Med Beauty" specialist centre for aesthetic medicine was opened in Vienna in December 2018, 7 foreign locations have been added in recent months. In addition to a further location in Austria (Linz), the company has successfully entered the markets in the Netherlands (Amsterdam, Rotterdam), Switzerland (Zurich) and Australia (Melbourne, Sydney, Brisbane).

Project pipeline gives reason to expect dynamic start to 2020

In addition, the project development for 10 further specialist centres - 5 of them in Great Britain alone - has been largely completed. The M1 Group is thus fully on track to achieve its goal: 50 specialist beauty centres by the end of 2020. M1 has already secured the necessary financing in September 2018 through a capital increase.


Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold shares in the aforementioned companies and that there may therefore be a conflict of interest. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

04. March 2020 | 07:27 CET

Medigene, Memphasys, Qiagen - which stocks belong in the portfolio?

  • Medical

In times of price fluctuations, so-called 'buy on dips' strategy can be an effective method of achieving a favorable entry price for listed companies. Global trends as a framework can be decisive for a successful investment decision. For a modern society, the healthcare sector has become a particularly important sector. In addition to the desire for a long life with health and care, there is also an increasing demand for products and therapies that can fulfil couples' desire to have children. There is a broad spectrum and as an investor it is worth taking a look at the companies.

Read

25. November 2019 | 05:54 CET

MPH Health Care investment HAEMATO with growth in Q3 - shares before turnaround?

  • Medical

HAEMATO AG, a provider of special pharmaceuticals and a subsidiary of MPH Health Care, which is also listed on the stock exchange, returned to growth in the third quarter of 2019. The company is also continuing to optimize its business processes and approve new products in order to broaden its portfolio. This means that the stocks could also face a turnaround. Analysts also see significant price potential.

Read

19. November 2019 | 07:35 CET

Expedeon AG before sale of a division to Abcam plc

  • Medical

The medical research company Expedeon has offices in Heidelberg and Madrid and develops innovative technologies, products and services that are used in research laboratories worldwide. Expedeon's products enable scientists to break down the boundaries of research and product development and make a significant contribution to the market launch of new diagnostic tools. With applications that cover the entire genomics, proteomics and immunology workflow, the technologies developed by Expedeon accelerate and simplify research and enable both biopharmaceutical and diagnostic companies and organizations to introduce new and cost-effective processes. Expedeon's products are distributed through direct sales and several distributors in Europe, the USA and Asia. The company has offices in Germany, Spain, United Kingdom, USA and Singapore.

Read